Introduction
Fibroblast growth factor 21 (FGF21), a member of the FGF family, functions as a hormone with a wide range of endocrine and autocrine actions on carbohydrate and lipid metabolism (1) and is considered a novel therapeutic target for the treatment of non-alcoholic fatty liver disease (NAFLD), insulin resistance and type 2 diabetes mellitus (T2DM). Several studies in genetic and diet-induced models of obesity have demonstrated that FGF21 administration ameliorates a large number of metabolic parameters (2) (3) (4) (5) , including plasma glucose and triglycerides levels and hepatic steatosis. However, despite these beneficial effects of administered FGF21, serum FGF21 levels are paradoxically increased in animal models of obesity (6) . Likewise, circulating FGF21 levels are also elevated in patients with obesity, hypertriglyceridemia, TDM2 or NAFLD (7) (8) (9) .
The pleiotropic effects of FGF21 on target tissues, including adipose tissue, -cells and liver (1, 10, 11) , are mediated by its binding to FGF receptors in a -klotho-dependent manner (12) (13) (14) .
-klotho is almost exclusively expressed in liver, adipose tissue, and pancreas (14) , which may explain why these specific tissues are the predominant sites of action of FGF21. Circulating FGF21 is liver-derived (15) , and hepatic FGF21 expression is upregulated, following extended periods of fasting, by Peroxisome Proliferator-Activated Receptor (PPAR), a nuclear receptor that induces the expression of numerous genes involved in mitochondrial fatty acid oxidation (16) .
In recent years, it has also been reported that FGF21 is regulated by additional transcription factors, including cyclic AMP response element-binding protein H (17) and retinoic acid receptor-related orphan receptor  (18) . Moreover, hepatic FGF21 is also negatively regulated by the PPAR coactivator 1 (PGC-1 by modulating the heme-sensing nuclear receptor REV-ERBwhich acts as a transcriptional repressor through its binding to ROR response elements (RORE) (19) .
Impaired mitochondrial oxidative phosphorylation is also responsible for Fgf21 induction by activating transcription factor 4 (ATF4). ATF4 is a transcriptional effector of the protein kinase R-like ER kinase (PERK)-branch of the endoplasmic reticulum (ER) stress/unfolded protein response pathway, which is essential for Fgf21-induced expression (20) . However, although it has been reported that circulating FGF21 is increased following treatment with PPAR/agonists (21) , little is known about the effects of PPAR/on FGF21 regulation in liver. PPAR/is a ligandactivated transcription factor involved in the regulation of glucose and lipid homeostasis (22) , and it has been proposed as a therapeutic target for the treatment of metabolic syndrome (23) . Thus, genetic manipulations of PPAR/as well as it activation by agonists attenuates dyslipidemia and hyperglycemia, improves whole-body insulin sensitivity, and prevents diet-induced obesity (24) . In this study, we examined the effects of PPAR/deficiency on hepatic Fgf21 expression. Ppar/-null mice showed enhanced hepatic Fgf21 expression, which appears to be dependent on a reduction in PGC-1levels and the subsequent reduction in hemin levels that finally activates the heme-regulated eIF2kinase (HRI). This kinase phosphorylates the eIF2, which in turn increases ATF4 levels, resulting in enhanced Fgf21 expression. Overall, our findings point to HRI as a new therapeutic target for regulating Fgf21 expression and metabolic dysregulation. Lipid-containing media were prepared by conjugation of palmitic acid with fatty acid-free bovine serum albumin, as previously described (27) . Primary mouse hepatocytes were isolated from nonfasting male C57BL/6 mice (10-12 weeks old) by perfusion with collagenase as described elsewhere (28 ) were treated as described in the third study.
Research Design and Methods

Reagents
RNA preparation and quantitative RT-PCR
The relative levels of specific mRNAs were assessed by Real-Time RT-PCR, as previously described (27) . Primer sequences used for Real-Time RT-PCR are displayed in Supplementary   Table 1 .
Immunoblotting
Western blot analyses were performed as previously indicated (27) .
Heme Protein Content Quantification
Heme content in liver was quantified by measuring the oxidized version of this protein, hemin, using an enzymatic assay kit (Hemin Assay Kit) (Sigma-Aldrich).
Oil Red Staining
Lipid accumulation in hepatocytes was assessed by Oil Red O staining as previously reported (29) .
Statistical Analyses
Results are expressed as means  S.D. Significant differences were established by one-way ANOVA using the GraphPad Instat program (GraphPad Software V5.01) (GraphPad Software Inc., San Diego, CA). When significant variations were found by one-way ANOVA, the Tukey-Kramer multiple comparison post-test was performed. Differences were considered significant at p<0.05.
Results
Ppar/ -/-mice show increased hepatic Fgf21 expression and plasma levels
PPAR/ -/-mice displayed higher hepatic Fgf21 mRNA levels than wild-type litter mates (3-fold induction, p<0.001) (Fig. 1A) . Consistent with the fact that circulating FGF21 is liver-derived (15), we found increased plasma FGF21 levels in Ppar/-deficient mice (2.6-fold increase, p<0.001) (Fig. 1B) and reduced expression of one of the receptor and co-receptor pairs used by FGF21, Fgfr1c (49 % reduction, p<0.05) and -Klotho (57 % reduction, p<0.001) (Fig. 1C) . Carnitine palmitoyl-transferase 1 a (Cpt-1a), 3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2) (30), 3--hydroxysteroid dehydrogenase type 5 (Hsd3b5) (31) and major urinary protein 1 (Mup1) (31) are FGF21 responsive genes. In accordance with increased FGF21 plasma levels, hepatic expression of Cpt-1a and Hmgcs2 was increased, whereas the expression of Hsd3b5, and the mRNA and protein levels of MUP1 were decreased in Ppar -/-mice ( Fig. 1D, Supplementary Fig. 1A ). In agreement with the reported observation of increased glucose uptake in adipocytes through enhanced Glut1 expression by FGF21 secreted by the liver (32), the expression of this glucose transporter was higher in white adipose tissue of Ppar -/-mice than in wild-type animals (Fig. 1E) . In contrast to the liver, the expression of Fgf21 in white adipose tissue was not significantly increased in
Ppar/-deficient mice (Fig. 1E ), pointing to a tissue-specific effect. Since increased serum free fatty acids (FFA) (33) and glucose levels (34) are two important stimuli that upregulate Fgf21 expression in liver, we measured their levels in serum of Ppar -/-and wild-type mice. No differences were observed in serum FFA and glucose levels ( Supplementary Fig. 1B and C), suggesting that they were not involved in the reported increase in Fgf21 expression. In addition, the expression levels of Pparand its target genes Acox and Mcad were not significantly increased, rendering it unlikely that PPAR is involved in the increase in Fgf21 expression in these mice ( Supplementary Fig. 1D ). Ppar/-null mice did not present upregulation of Chop, Orp150 or Atf3 expression ( Supplementary Fig. 1E ) nor of phospho-IRE1and BiP levels (Supplementary Figure 1F) , suggesting that ER stress was not the stimulus responsible for the increase in Fgf21 expression. Primary hepatocytes were transfected with either control siRNA or
Ppar/siRNA showed a significant reduction (71%, p<0.001) in this transcription factor (Supplementary Fig. 1G ) and a significant increase in Fgf21 gene expression (Fig. 1F) (Fig. 2F ). In agreement with the increase in HRI, levels of the downstream proteins of this pathway, phospho-eIF2and ATF4, were also upregulated (Fig. 2F ).
In accordance with the findings observed in the liver of Ppar/-deficient mice, siRNA knockdown of Ppar/ in primary hepatocytes led to enhanced protein levels of HRI, phosphoeIF2, ATF4 and reduced levels of MUP1 (Fig. 3A) . Transfection of primary hepatocytes with siRNA against Hri caused a significant reduction in hemin levels and in the expression of Fgf21, Atf4 and Chop. The latter being a direct ATF4 transcriptional target (43) used as a marker of the activation of the eIF2-ATF4 pathway following activation of HRI (25) (Fig. 3B-E) . Likewise, the protein levels of phosphorylated eIF2ATF4 and CHOP were decreased, whereas the protein levels of MUP1 were increased ( Fig. 3F ), confirming through a genetic approach that HRI controls Fgf21 expression in hepatocytes.
PPAR/regulates ER stress through hepatic Fgf21 expression
Hepatic Fgf21 expression increases in response to ER stressors in liver, where it seems to play an adaptive response to these stimuli (44) . In fact, exogenous administration of FGF21 alleviates the tunicamycin-induced eIF2-ATF4-CHOP pathway, whereas it shows an insignificant effect on the IRE1-XBP1s pathway (44) . We hypothesized that the increase in FGF21 levels in Ppar/-deficient mice may protect the liver against ER stress, which is consistent with the fact that, in contrast to the liver, skeletal muscle of these mice showed increased expression of ER stress suggesting that the higher levels of FGF21 in Ppar -/-mice inhibited the phosphorylation of eIF2, as previously described (44) . To clearly demonstrate this, we used an FGF21 neutralizing antibody. In wild-type mice, treatment with the FGF21 neutralizing antibody for 14 h did not significantly affect eIF2phosphorylation compared to IgG-treated mice ( Supplementary Fig. 2B ).
In contrast, when Ppar -/-mice were treated with the FGF21 neutralizing antibody for the same amount of time, a significant increase was observed in phospho-eIF2levels (Fig. 4D ). Ppar -/-mice treated for 14 h with tunicamycin and IgG showed a reduction in the levels of phosphoeIF2, suggesting that the additional increase in FGF21 levels caused by tunicamycin treatment was responsible for this effect. In line with this, injection of the FGF21 neutralizing antibody raised phospho-eIF2levels (Fig. 4D ). The protein levels of ATF4 also showed an increase following treatment with the FGF21 neutralizing antibody (Fig. 4D ). Through its negative action on eIF2 and ATF4, FGF21 can activate a negative feedback loop that reduces Fgf21 expression (44) . Consistently, administration of the FGF21 neutralizing antibody raised the mRNA levels of Fgf21 (Fig. 4E) . The increase in BiP and Atf3 expression and BiP protein levels confirmed that tunicamycin treatment for 14 h resulted in ER stress ( Supplementary Fig. 2C-E) .
Next, we explored whether the described mechanisms also operated in human HepG2 cells.
Treatment with Ppar/ siRNA led to a significant increase in phosphorylated eIF2 and ATF4 levels ( Fig. 4F) , confirming that Ppar/deficiency activates the eIF2-ATF4 pathway. In addition, in the presence of the FGF21 neutralizing antibody, the increase in phospho-eIF2 and especially in ATF4 was exacerbated compared with IgG-treated cells. We then examined the effects of the FGF21 neutralizing antibody on tunicamycin-treated cells. In these cells, the FGF21
neutralizing antibody increased the levels of phosho-eIF2 and ATF4 protein levels compared with IgG-treated cells (Fig. 4F) . Overall, these findings confirm that an increase in FGF21 levels in Ppar -/-mice prevents an increase in the eIF2-ATF4 pathway, alleviating part of the ER stress process in liver.
PPAR/ activation prevents the increase in the HRI kinase-eIF2-ATF4 pathway caused by a HFD in liver
Interestingly, exposure to a HFD increases Fgf21 expression (11), and we have previously reported that exposure to HFD reduces hepatic mRNA levels of Pgc-1 (46) . This suggests that exposure to a HFD might activate the HRI-eIF2-ATF4 pathway, contributing to an increase in hepatic Fgf21 expression. In mice exposed to a HFD for 3 weeks in the presence or absence of the PPAR/ activator GW501516 we observed that the HFD increased hepatic Fgf21 expression (8-fold increase, P<0.05), whereas this increase was prevented by GW501516 (Fig. 5A) . Consistent with the changes in Fgf21 expression, feeding a HFD reduced MUP1 protein levels, whereas the PPAR/agonist prevented the decrease caused by the HFD (Fig. 5B) . No change was observed in the protein levels of the ER stress marker BiP ( Supplementary Fig. 3A ), rendering it unlikely that ER stress might be responsible for the increase in Fgf21 expression caused by a HFD.
Interestingly, the HFD strongly reduced the protein levels of PPAR/, PGC-1and REV-ERB, whereas ATF4 protein levels were increased (Fig. 5C ). In contrast, these changes were abolished in mice fed the HFD and treated with GW501516. Furthermore, the reduction in PPAR/, PGC-1
and REV-ERBwas accompanied by a reduction in hemin levels ( Supplementary Fig. 3B ) and an increase in HRI levels in mice fed the HFD, whereas this increase was blunted following drug treatment ( Supplementary Fig. 3B and Fig. 5D ). To confirm whether FAs were the HFD component responsible for the changes observed in the in vivo study, we exposed human Huh-7
hepatocytes to the SFA palmitate. Cells incubated with palmitate showed a huge increase in FGF21 and ATF4 expression (Fig. 5E ). Palmitate also elicited a reduction in PPAR/, PGC-1
and REV-ERB and a subsequent increase in HRI, phospho-eIF2and ATF4 protein levels (Fig.   5F ). These findings suggest that by reducing PPAR/and PGC-1 SFA lead to activation of the HRI-eIF2-ATF4 pathway and a subsequent increase in FGF21 expression.
HRI is a pharmacological target to modulate hepatic Fgf21 expression
Given that HRI regulates FGF21, we next explored its suitability as a pharmacological target to modulate hepatic FGF21 expression. For this purpose we used two N,N'-diarylureas, BTdCPU and BTCtFPU, which are HRI activators, thereby causing the phosphorylation of eIF2 and the increased expression of the transcription factor ATF4 (25) . Exposure of human Huh-7 hepatocytes to either 10 M BTdCPU or BTCtFPU for 24 h strongly increased Fgf21 and Atf4 mRNA levels ( Fig. 6A and B) . The increase in the expression of CHOP (Fig. 6C) , a direct ATF4 transcriptional target (43) , confirmed that this pathway was activated by the N,N'-diaylureas. These compounds did not increase PPARnor its target genes, nor BiP mRNA ( Supplementary Fig. 4A-D) , nor BiP protein levels (Fig. 6D) , suggesting that these mechanisms were not involved in Fgf21 upregulation. In line with the reported activation of HRI by these N,N'-diarylurea compounds, we observed increased protein levels of phospho-eIF2and ATF4, especially following treatment with BTdCPU (Fig. 6D) . Treatment of mice with BTdCPU for one week also increased hepatic Fgf21 expression (Fig. 6E) , without changes in BiP protein levels, whereas phospho-eIF2 and ATF4
were increased (Fig. 6F) . Moreover, consistent with the increased expression of Fgf21, Glut1 mRNA levels were higher in the white adipose tissue of mice treated with BTdCPU (Fig. 6G) .
Next, we explored the effects of BTdCPU on human Huh-7 hepatocytes exposed to the SFA palmitate. Cells exposed to this FA showed increased FGF21, ATF4 and CHOP mRNA levels and when cells were co-incubated with the FA and BTdCPU, a significant higher increase was observed in the expression of these three genes (Fig. 7A) . Interestingly, when HuH7 cells were exposed to palmitate, a high accumulation of triglycerides was observed in the cells, as demonstrated by Oil Red O (ORO) staining, but this accumulation was prevented in the presence of the BTdCPU compound, and this effect was attenuated in the presence of the FGF21 neutralizing antibody (Fig. 7B and Supplementary Fig. 5A ). Similar effects were observed in mouse Hepa-1c1c7 hepatocytes ( Supplementary Fig. 5B ). Likewise, this compound partially restored the reduction in insulin-stimulated Akt phosphorylation caused by palmitate ( Fig. 7C and Supplementary Fig. 5C ), showing that this drug treatment prevents SFA-induced attenuation of the insulin signaling pathway. Next, we examined the effects of the BTdCPU compound in mice fed a HFD. Of note, BTdCPU administration prevented the glucose intolerance caused by HFD feeding (Fig. 7D) , increased Glut1 expression in white adipose tissue (Fig. 7E) and prevented hepatic steatosis, as demonstrated by ORO and eosin-hematoxylin staining and quantification of hepatic triglyceride levels ( Fig. 7F and G) . Drug treatment did not affect the expression of PPAR-target genes ( Supplementary Fig. 5D and E), whereas the expression of the lipogenic gene fatty acid synthase (Fas) and stearoyl-CoA desaturase 1 (Scd1) was reduced (Supplementary Figure 5F and G), which is consistent with the reported reduction of these genes by FGF21 (47) .
To clearly demonstrate that the improvement in glucose tolerance and hepatic steatosis caused by the administration of the HRI activator in mice fed a HFD is dependent on FGF21 we used WT and Fgf21-null mice. The reduction in glucose intolerance observed in WT mice fed a HFD caused by administration of the HRI activator was completely abolished in Fgf21-null mice (Fig. 8A), suggesting that in the absence of FGF21 the effect of the HRI activator on glucose tolerance is lost.
Similarly, the reduction in hepatic triglyceride accumulation in WT fed a HFD caused by BTdCPU administration was suppressed in Fgf21-null mice, as demonstrated by the analysis of the levels of triglyceride and the ORO and eosin-hematoxylin staining ( Fig. 8B and C) .
Discussion
FGF21 has emerged as an important regulator of glucose and lipid metabolism and hence is a promising agent for the treatment of obesity, NAFLD, insulin resistance and type 2 diabetes mellitus. Unraveling the mechanisms that regulate Fgf21 expression in liver may provide pharmacological targets for modulating its expression to prevent metabolic diseases. In this study, we demonstrate that Ppar/-null mice show enhanced hepatic Fgf21 expression and circulating levels of this hormone. Ppar/deficiency caused a reduction in transcriptional co-activator PGC1levels that resulted in a reduction in hemin levels and the subsequent activation of HRI and the eIF2-ATF4 pathway, which is essential for Fgf21-induced expression (Fig. 8) . Likewise, activation of this pathway could be an additional mechanism that can contribute to the increase in The finding that Ppar/deficiency upregulates Fgf21 expression in liver was unexpected since it has previously been reported that pharmacological activation of this nuclear receptor increases FGF21 levels (21) . The latter is consistent with the discovery of two putative peroxisome proliferator response elements (PPRE) in the mouse and human FGF21 promoters (48) and with the fact that both PPAR and PPARactivators increase FGF21 levels in hepatocytes and adipocytes, respectively. However, genetically reduced PGC-1, a transcriptional co-activator that controls the expression and activity of PPARs and is also regulated by these transcription factors, likewise results in increased FGF21 levels (19) . In fact, it has been reported that reduced hepatic PGC-1 upregulates Fgf21 expression by reducing REV-ERBand the levels of its ligand heme.
This alleviated the repressive activity of REV-ERB on the Fgf21 promoter leading to enhanced
Fgf21 expression. In the present study, we show that Ppar/deficiency results in a reduction in PGC-1 levels that leads to a reduction in REV-ERB and hemin, the oxidized form of heme, suggesting that this mechanism can also contribute to an increase in Fgf21 expression in the liver of Ppar/-null mice. In addition, our findings also provide a new biochemical pathway that can contribute to the enhanced expression of Fgf21 in the liver of these mice. Indeed, the reduction in heme can increase HRI levels (43), which in turn can activate the eIF2-ATF4 pathway, where the increase in ATF4 is one of the most important transcription factors that upregulate Fgf21 expression. In fact, it has been reported that overexpression of ATF4 induces Fgf21 expression (20) , whereas knockdown of Atf4 reduces basal and ER stress-induced Fgf21 expression (49).
Therefore, our findings indicate that Ppar/deficiency in liver results in increased levels of ATF4 and a subsequent increase in Fgf21 expression. The increase in ATF4 levels seems to be a crucial step in Fgf21 upregulation, since this transcription factor is involved in the increase of this hormone in impaired mitochondrial OXPHOS induced by autophagy deficiency (20) , ER stress (49), metformin-induced inhibition of the mitochondrial respiratory chain (50) and now PPAR/-PGC-1deficiency, as shown by this study.
The eIF2-ATF4 pathway is activated by ER stress leading to enhanced Fgf21 expression, which in turn alleviates ER stress by suppressing this eIF2-ATF4 pathway, as has been demonstrated by injection of recombinant FGF21 (44) . By using a neutralizing antibody against FGF21, we have confirmed that this negative feedback is also activated by FGF21.
Interestingly, the reduction in PPAR/ and PGC-1 following exposure to a HFD might also contribute to increased Fgf21 expression. In fact, livers of mice exposed to a HFD or hepatocytes exposed to the saturated fatty acid palmitate showed reduced PPAR/and PGC-1levels, resulting in an increase in the levels of HRI and subsequent activation of the eIF2-ATF4 pathway.
These findings suggest that activation of this pathway could also contribute to the increase in FGF21 in those conditions associated with fat overfeeding, such as obesity, type 2 diabetes mellitus, or NAFLD, which show increased levels of this hormone (7) (8) (9) . In contrast, activation of PPAR/ under conditions of lipid overload recovers PGC-1 levels and attenuates the eIF2-ATF4 pathway, restoring Fgf21 expression.
The regulation of FGF21 by the eIF2kinase HRI provides a target for regulation of the levels of this hormone to prevent or treat metabolic diseases, including NAFLD, insulin resistance, and diabetes. N,N'-diarylureas are activators of HRI that cause phosphorylation of eIF2developed as anticancer drugs (25) . Here we show that these drugs can increase Fgf21 expression in hepatocytes and that their administration to mice fed a HFD prevents the accumulation of triglycerides in liver and improves glucose intolerance. This is consistent with the fact that liver-specific Fgf21 knockout mice fed a HFD displayed glucose intolerance and increased hepatic lipid accumulation (15) . Moreover, we have demonstrated that the improvement in glucose tolerance and hepatic steatosis caused by the HRI activator BTdCPU in mice fed a HFD is dependent on FGF21, since it was not observed in Fgf21-null mice.
In summary, on the basis of our findings we propose that Ppar/deficiency results in a reduction in hepatic PGC-1and hemin levels that in turn increase HRI levels, leading to activation of the eIF2-ATF4 pathway and a subsequent increase in Fgf21 expression. Moreover, pharmacological activation of the eIF2 kinase HRI increases Fgf21 expression and treatment with a drug that activates HRI prevents glucose intolerance and hepatic triglyceride accumulation in mice fed a HFD. These findings point to HRI as a target for the treatment of metabolic diseases by modulating FGF21 levels. Step 2. 6-Nitro-1,2,3-benzothiadiazole 3
ACKNOWLEDGMENTS-R. L. thanks the Spanish Ministry of Education for a PhD
11.68 g (34. Step 3. 6-Amino-1,2,3-thiadiazole 4 2 g (11.0 mmol) 6-nitro-1,2,3-benzothiadiazole 3 was added to a solution of 10.6 g tin (II) chloride in concentrated hydrochloric acid (16 mL) at 55 °C, using a water bath to maintain that temperature. The reaction mixture was heated to 70 °C for 10 min, then cooled to 4 °C and let stand for 18 h. The crystalline precipitate was collected and washed with ice cold water. The solid was dissolved in water (40 mL) and 10 N sodium hydroxide (10 mL) was added followed by ethyl acetate (30 mL) and the mixture was 
